Key result
Sodium-glucose cotransporter-2 inhibitors significantly reduce heart failure hospitalizations and cardiovascular mortality in patients with heart failure with preserved ejection fraction.
Why the study?
Heart failure with preserved ejection fraction presents a major clinical challenge due to its complex pathophysiology and limited therapeutic options.
Do sodium-glucose cotransporter-2 inhibitors reduce heart failure hospitalizations and cardiovascular mortality in patients with heart failure with preserved ejection fraction?
Do sodium-glucose cotransporter-2 inhibitors reduce heart failure hospitalizations and cardiovascular mortality in patients with heart failure with preserved ejection fraction?
SGLT2 inhibitors are an effective and guideline-supported therapy for managing HFpEF, offering significant reductions in hospitalizations and improvements in quality of life across diverse patient subgroups.
Heart failure with preserved ejection fraction presents a major clinical challenge due to its complex pathophysiology and limitations in its therapeutic options. This comprehensive review explores the comparative effectiveness of sodium-glucose cotransporter-2 inhibitors, focusing on their impact on diabetic versus non-diabetic patients, individuals with chronic kidney disease, and the elderly. A comprehensive literature search identified randomized controlled trials, meta-analyses, and clinical studies that evaluated the role of sodium-glucose cotransporter-2 inhibitors in managing heart failure with preserved ejection fraction. Findings indicate that sodium-glucose cotransporter-2 inhibitors significantly reduce heart failure hospitalizations and cardiovascular mortality. Among chronic kidney disease patients with heart failure with preserved ejection fraction, sodium-glucose cotransporter-2 inhibitors showed a decrease in the risk of cardiovascular mortality and hospitalization. Furthermore, their use in elderly patients was associated with improved health-related quality of life and cognitive function, with no notable increase in adverse events. Clinical guidelines increasingly recommend sodium-glucose cotransporter-2 inhibitors as part of heart failure with preserved ejection fraction management. However, further research is required to refine patient-specific strategies and explore additional benefits, such as their cardioprotective role post-myocardial infarction. This review highlights the effectiveness of sodium-glucose cotransporter-2 inhibitors in managing heart failure with preserved ejection fraction across various subgroups. Additionally, integrating these agents into clinical practice has significant potential to improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Alsuwayh et al. (2024) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Sodium-glucose cotransporter-2 (SGLT2) inhibitors vs. Placebo or standard of care was evaluated. Sodium-glucose cotransporter-2 inhibitors significantly reduce heart failure hospitalizations and cardiovascular mortality in patients with heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: